Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2676| Título : | ADE as Induction Therapy Results in Treatment of Children with Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries |
| Creador: | Zapata Tarrés, Martha |
| Nivel de acceso: | Open access |
| Palabras clave : | Leucemia Mieloide Aguda - terapia Leucemia Mieloide Aguda - genética Leucemia Mieloide Aguda - diagnóstico Leucemia Mieloide Aguda - mortalidad Leucemia Mieloide Aguda - sangre Citarabina - uso terapéutico Etopósido - uso terapéutico femenino niño masculino Citogenética población Neoplasias - mortalidad Leukemia, Myeloid, Acute - therapy Leukemia, Myeloid, Acute - genetics, Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - mortality Cytarabine -Therpeutic use Etoposide - Therpeutic use female niño male Cytogenetics Population Neoplasms - mortality Leucemia mieloide aguda, niño, terapia, Acute Myeloid Leukemia, Children, Treatment, ADE |
| Descripción : | In Mexico, AML survival is referred in 30%. Our aim was to evaluate results with ADE protocol as induction treatment in children with non-M3 AML in a public Mexican institution. Method: We included patients with AML in a single institution between 2005 and 2013. All nonM3-AML patients received ADE as induction therapy (cytarabine 100 mg/m2 in continuous infusion from day 1 to 7, daunorrubicin 30 mg/m2 days 1, 3, 5 and etoposide 100 mg/m2 over days 1 to 5). Patients received antibiotic prophylaxis and strict scheduled appointments to assure adherence and prevent avoidable emergencies. Main Results: Eighteen patients were included. Median age was 106 months. One patient died at diagnosis so 17 were eligible for induction results analysis; eleven needed two cycles and six patients three. Remission rate was 100%. Analyzing non-M3 patients overall survival was 80.2% at 100 months. No fatal complications were observed. Stratifying by number of cycles we observe that patients receiving one ADE cycle had a 0% overall survival at short follow up, with 2 ADE cycles 80% at 100 months and with 3 cycles 100% at 60 months. Conclusion: ADE induction therapy showed improved results in overall survival compared with other standard regimens. Following the protocol we obtained 100% remission. This is |
| Colaborador(es) u otros Autores: | Cárdenas-Cardós Rocío Velasco-Hidalgo Liliana Pérez-García Martín Olaya-Vargas Alberto Cárdenas-Pedraza Daniela Rivera-Luna Roberto |
| Fecha de publicación : | 2016 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.4236/jct.2016.73020 |
| Fuente: | Journal of Cancer Therapy 7():197 - 202 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2676 |
| Idioma: | spa |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.